Complement C5a: Impact on the field of veterinary medicine

Veterinary Journal

Volumn 192, Issue 3, 2012, Pages 264-271

  Hezmee, M N M ^a,b   Shiels, I A ^a   Rolfe, B E ^a   Mills, P C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Agonist; Antagonist; C5a receptor (C5aR); Complement; Complement factor 5a (C5a)

Indexed keywords

ADC 1004; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; IMMUNOMODULATING AGENT; PMX 53; UNCLASSIFIED DRUG; W 54011;

ADAPTIVE IMMUNITY; ARTHRITIS; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; COMPLEMENT SYSTEM; DEGENERATIVE DISEASE; DISEASE COURSE; DRUG MECHANISM; ENTERITIS; HEART INFARCTION; HUMAN; HYPOTENSION; INFLAMMATION; INNATE IMMUNITY; NEUTROPENIA; NONHUMAN; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEPSIS; VETERINARY MEDICINE;

ANIMAL DISEASES; ANIMALS; COMPLEMENT C5A; GENE EXPRESSION REGULATION; INFLAMMATION; PETS;

ANIMALIA; MUS;

EID: 84861875420     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.12.008     Document Type: Review

References (133)

1. Albrecht E.A., Chinnaiyan A.M., Varambally S., Kumar-Sinha C., Barrette T.R., Sarma J.V., Ward P.A. C5a-induced gene expression in human umbilical vein endothelial cells. American Journal of Pathology 2004, 164:849-859.
2. Alvarez V., Coto E., Setien F., Gonzalez-Roces S., Lopez-Larrea C. Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates. Immunogenetics 1996, 44:446-452.
3. Arumugam T.V., Shiels I.A., Woodruff T.M., Reid R.C., Fairlie D.P., Taylor S.M. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. Journal of Surgical Research 2002, 103:260-267.
4. Arumugam T.V., Shiels I.A., Strachan A.J., Abbenante G., Fairlie D.P., Taylor S.M. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney International 2003, 63:134-142.
5. Arumugam T.V., Shiels I.A., Woodruff T.M., Granger D.N., Taylor S.M. The role of the complement system in ischemia-reperfusion injury. Shock 2004, 21:401-409.
6. Arumugam T.V., Magnus T., Woodruff T.M., Proctor L.M., Shiels I.A., Taylor S.M. Complement mediators in ischemia-reperfusion injury. Clinica Chimica Acta 2006, 374:33-45.
7. Arumugam T.V., Woodruff T.M., Lathia J.D., Selvaraj P.K., Mattson M.P., Taylor S.M. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009, 158:1074-1089.
8. Atefi G., Zetoune F.S., Herron T.J., Jalife J., Bosmann M., Al-Aref R., Sarma J.V., Ward P.A. Complement dependency of cardiomyocyte release of mediators during sepsis. FASEB Journal 2011, 25:2500-2508.
9. Bachvarov D.R., Houle S., Bachvarova M., Bouthillier J., St.-Pierre S.A., Fukuoka Y., Ember J.A., Marceau F. Cloning and preliminary pharmacological characterization of the anaphylatoxin C5a receptor in the rabbit. British Journal of Pharmacology 1999, 128:321-326.
10. Bamberg C.E., Mackay C.R., Lee H., Zahra D., Jackson J., Lim Y.S., Whitfeld P.L., Craig S., Corsini E., Lu B., Gerard C., Gerard N.P. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. Journal of Biological Chemistry 2010, 285:7633-7644.
11. Bhatia M., Saluja A.K., Singh V.P., Frossard J.L., Lee H.S., Bhagat L., Gerard C., Steer M.L. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury. American Journal of Physiology - Gastrointestinal and Liver Physiology 2001, 280:G974-978.
12. Bhole D., Stahl G.L. Therapeutic potential of targeting the complement cascade in critical care medicine. Critical Care Medicine 2003, 31:S97-104.
13. Bokisch V.A., Muller-Eberhard H.J. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. Journal of Clinical Investigation 1970, 49:2427-2436.
14. Buchner R.R., Vogen S.M., Fischer W., Thoman M.L., Sanderson S.D., Morgan E.L. Anti-human kappa opioid receptor antibodies: Characterization of site-directed neutralizing antibodies specific for a peptide kappa R(33-52) derived from the predicted amino terminal region of the human kappa receptor. Journal of Immunology 1997, 158:1670-1680.
15. Buhl A.M., Avdi N., Worthen G.S., Johnson G.L. Mapping of the C5a receptor signal transduction network in human neutrophils. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:9190-9194.
16. Chen N.J., Mirtsos C., Suh D., Lu Y.C., Lin W.J., McKerlie C., Lee T., Baribault H., Tian H., Yeh W.C. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007, 446:203-207.
17. Chen M., Daha M.R., Kallenberg C.G. The complement system in systemic autoimmune disease. Journal of Autoimmunity 2010, 34:J276-286.
18. Chenoweth D.E., Hugli T.E. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proceedings of the National Academy of Sciences of the United States of America 1978, 75:3943-3947.
19. Cork L.C., Morris J.M., Olson J.L., Krakowka S., Swift A.J., Winkelstein J.A. Membranoproliferative glomerulonephritis in dogs with a genetically determined deficiency of the third component of complement. Clinical Immunology and Immunopathology 1991, 60:455-470.
20. Damerau B., Grunefeld E., Vogt W. Chemotactic effects of the complement-derived peptides C3a, C3ai and C5a (classical anaphylatoxin) on rabbit and guinea-pig polymorphonuclear leukocytes. Naunyn-Schmiedeberg's Archives of Pharmacology 1978, 305:181-184.
21. Drouin S.M., Sinha M., Sfyroera G., Lambris J.D., Wetsel R.A. A protective role for the fifth complement component (c5) in allergic airway disease. American Journal of Respiratory and Critical Care Medicine 2006, 173:852-857.
22. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Research 2010, 20:34-50.
23. Duryee M.J., Bevins R.A., Reichel C.M., Murray J.E., Dong Y., Thiele G.M., Sanderson S.D. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 2009, 27:2981-2988.
24. Fearon D.T., Carroll M.C. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annual Review of Immunology 2000, 18:393-422.
25. Finch A.M., Vogen S.M., Sherman S.A., Kirnarsky L., Taylor S.M., Sanderson S.D. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity. Journal of Medicinal Chemistry 1997, 40:877-884.
26. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., Taylor S.M. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. Journal of Medicinal Chemistry 1999, 42:1965-1974.
27. Frank M.M. Animal models for complement deficiencies. Journal of Clinical Immunology 1995, 15:113S-121S.
28. Fukuoka Y., Ember J.A., Yasui A., Hugli T.E. Cloning and characterization of the guinea pig C5a anaphylatoxin receptor: Interspecies diversity among the C5a receptors. International Immunology 1998, 10:275-283.
29. Gao H., Neff T.A., Guo R.F., Speyer C.L., Sarma J.V., Tomlins S., Man Y., Riedemann N.C., Hoesel L.M., Younkin E., Zetoune F.S., Ward P.A. Evidence for a functional role of the second C5a receptor C5L2. FASEB Journal 2005, 19:1003-1005.
30. Gerard N.P., Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature 1991, 349:614-617.
31. Gerard N.P., Hodges M.K., Drazen J.M., Weller P.F., Gerard C. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. Journal of Biological Chemistry 1989, 264:1760-1766.
32. Gerard C., Bao L., Orozco O., Pearson M., Kunz D., Gerard N.P. Structural diversity in the extracellular faces of peptidergic G-protein-coupled receptors. Molecular cloning of the mouse C5a anaphylatoxin receptor. Journal of Immunology 1992, 149:2600-2606.
33. Gomez-Cambronero J., Di Fulvio M., Knapek K. Understanding phospholipase D (PLD) using leukocytes: PLD involvement in cell adhesion and chemotaxis. Journal of Leukocyte Biology 2007, 82:272-281.
34. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annual Review of Immunology 2005, 23:821-852.
35. Guo R.F., Riedemann N.C., Ward P.A. Role of C5a-C5aR interaction in sepsis. Shock 2004, 21:1-7.
36. Hajishengallis G. Complement and periodontitis. Biochemical Pharmacology 2011, 80:1992-2001.
37. Hangen D.H., Stevens J.H., Satoh P.S., Hall E.W., O'Hanley P.T., Raffin T.A. Complement levels in septic primates treated with anti-C5a antibodies. Journal of Surgical Research 1989, 46:195-199.
38. Hatherill J.R., Stephens K.E., Nagao K., Ishizaka A., Wilmarth L., Wang J.C., Deinhart T., Larrick J.W., Raffin T.A. Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: Chemotaxis, chemiluminescence, and lysosomal enzyme release. Journal of Biological Response Modifiers 1989, 8:614-624.
39. Haviland D.L., McCoy R.L., Whitehead W.T., Akama H., Molmenti E.P., Brown A., Haviland J.C., Parks W.C., Perlmutter D.H., Wetsel R.A. Cellular expression of the C5a anaphylatoxin receptor (C5aR): Demonstration of C5aR on nonmyeloid cells of the liver and lung. Journal of Immunology 1995, 154:1861-1869.
40. Hawlisch H., Wills-Karp M., Karp C.L., Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Molecular Immunology 2004, 41:123-131.
41. Hegde G.V., Meyers-Clark E., Joshi S.S., Sanderson S.D. A conformationally-biased, response-selective agonist of C5a acts as a molecular adjuvant by modulating antigen processing and presentation activities of human dendritic cells. International Immunopharmacology 2008, 8:819-827.
42. Hezmee M.N., Kyaw-Tanner M., Lee J.Y., Shiels I.A., Rolfe B., Woodruff T., Mills P.C. Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors. Veterinary Immunology and Immunopathology 2011, 139:50-56.
43. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., Roth A., Szer J., Elebute M.O., Nakamura R., Browne P., Risitano A.M., Hill A., Schrezenmeier H., Fu C.L., Maciejewski J., Rollins S.A., Mojcik C.F., Rother R.P., Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine 2006, 355:1233-1243.
44. Hillmen P., Muus P., Duhrsen U., Risitano A.M., Schubert J., Luzzatto L., Schrezenmeier H., Szer J., Brodsky R.A., Hill A., Socie G., Bessler M., Rollins S.A., Bell L., Rother R.P., Young N.S. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110:4123-4128.
45. Hopken U.E., Lu B., Gerard N.P., Gerard C. The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 1996, 383:86-89.
46. Huber-Lang M.S., Sarma J.V., McGuire S.R., Lu K.T., Guo R.F., Padgaonkar V.A., Younkin E.M., Laudes I.J., Riedemann N.C., Younger J.G., Ward P.A. Protective effects of anti-C5a peptide antibodies in experimental sepsis. FASEB Journal 2001, 15:568-570.
47. Huber-Lang M.S., Riedeman N.C., Sarma J.V., Younkin E.M., McGuire S.R., Laudes I.J., Lu K.T., Guo R.F., Neff T.A., Padgaonkar V.A., Lambris J.D., Spruce L., Mastellos D., Zetoune F.S., Ward P.A. Protection of innate immunity by C5aR antagonist in septic mice. FASEB Journal 2002, 16:1567-1574.
48. Janeway C.A.J., Travers P., Walport M. The complement system and innate immunity. Immunobiology: The Immune System in Health and Disease 2001, vol. 1:43-44. Garland Science, New York.
49. Jansen J.H., Hogasen K., Mollnes T.E. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). American Journal of Pathology 1993, 143:1356-1365.
50. Johswich K., Martin M., Bleich A., Kracht M., Dittrich-Breiholz O., Gessner J.E., Suerbaum S., Wende E., Rheinheimer C., Klos A. Role of the C5a receptor (C5aR) in acute and chronic dextran sulfate-induced models of inflammatory bowel disease. Inflammatory Bowel Diseases 2009, 15:1812-1823.
51. Kiener H.P., Baghestanian M., Dominkus M., Walchshofer S., Ghannadan M., Willheim M., Sillaber C., Graninger W.B., Smolen J.S., Valent P. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis and Rheumatism 1998, 41:233-245.
52. Kim A.H., Dimitriou I.D., Holland M.C., Mastellos D., Mueller Y.M., Altman J.D., Lambris J.D., Katsikis P.D. Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. Journal of Immunology 2004, 173:2524-2529.
53. Kim D.Y., Martin C.B., Lee S.N., Martin B.K. Expression of complement protein C5a in a murine mammary cancer model: Tumor regression by interference with the cell cycle. Cancer Immunology and Immunotherapy 2005, 54:1026-1037.
54. Kim G.H., Mocco J., Hahn D.K., Kellner C.P., Komotar R.J., Ducruet A.F., Mack W.J., Connolly E.S. Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery 2008, 63:122-125. (discussion 125-126).
55. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology 1997, 38:51-62.
56. Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Molecular Immunology 2009, 46:2753-2766.
57. Kodani M., Sakata N., Takano Y., Kamiya H., Katsuragi T., Hugli T.E., Abe M. Intratracheal administration of anaphylatoxin C5a potentiates antigen-induced pulmonary reactions through the prolonged production of cysteinyl-leukotrienes. Immunopharmacology 2000, 49:263-274.
58. Kohl J. Drug evaluation: The C5a receptor antagonist PMX-53. Current Opinion in Molecular Therapeutics 2006, 8:529-538.
59. Kohl J., Baelder R., Lewkowich I.P., Pandey M.K., Hawlisch H., Wang L., Best J., Herman N.S., Sproles A.A., Zwirner J., Whitsett J.A., Gerard C., Sfyroera G., Lambris J.D., Wills-Karp M. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. Journal of Clinical Investigation 2006, 116:783-796.
60. Krishnamoorthy S., Honn K.V. Inflammation and disease progression. Cancer and Metastasis Review 2006, 25:481-491.
61. Kurimoto Y., de Weck A.L., Dahinden C.A. Interleukin 3-dependent mediator release in basophils triggered by C5a. Journal of Experimental Medicine 1989, 170:467-479.
62. Laudes I.J., Chu J.C., Sikranth S., Huber-Lang M., Guo R.F., Riedemann N., Sarma J.V., Schmaier A.H., Ward P.A. Anti-c5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. American Journal of Pathology 2002, 160:1867-1875.
63. Lee H., Zahra D., Vogelzang A., Newton R., Thatcher J., Quan A., So T., Zwirner J., Koentgen F., Padkjaer S.B., Mackay F., Whitfeld P.L., Mackay C.R. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nature Biotechnology 2006, 24:1279-1284.
64. Lee H., Whitfeld P.L., Mackay C.R. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunology and Cell Biology 2008, 86:153-160.
65. Linton S.M., Morgan B.P. Complement activation and inhibition in experimental models of arthritis. Molecular Immunology 1999, 36:905-914.
66. Liu Z.M., Zhu S.M., Qin X.J., Cheng Z.D., Liu M.Y., Zhang H.M., Liu D.X. Silencing of C5a receptor gene with siRNA for protection from Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Molecular Immunology 2010, 47:1325-1333.
67. Macor P., Tedesco F. Complement as effector system in cancer immunotherapy. Immunology Letters 2007, 111:6-13.
68. Manthey H.D., Woodruff T.M., Taylor S.M., Monk P.N. Complement component 5a (C5a). International Journal of Biochemistry and Cell Biology 2009, 41:2114-2117.
69. Marc M.M., Kristan S.S., Rozman A., Kern I., Flezar M., Kosnik M., Korosec P. Complement factor C5a in acute exacerbation of chronic obstructive pulmonary disease. Scandinavian Journal of Immunology 2010, 71:386-391.
70. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nature Immunology 2008, 9:1225-1235.
71. McKinley L., Kim J., Bolgos G.L., Siddiqui J., Remick D.G. Allergens induce enhanced bronchoconstriction and leukotriene production in C5 deficient mice. Respiratory Research 2006, 7:129.
72. Mohr M., Hopken U., Oppermann M., Mathes C., Goldmann K., Siever S., Gotze O., Burchardi H. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. European Journal of Clinical Investigation 1998, 28:227-234.
73. Molina H., Holers V.M., Li B., Fung Y., Mariathasan S., Goellner J., Strauss-Schoenberger J., Karr R.W., Chaplin D.D. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:3357-3361.
74. Monk P.N., Scola A.M., Madala P., Fairlie D.P. Function, structure and therapeutic potential of complement C5a receptors. British Journal of Pharmacology 2007, 152:429-448.
75. Morgan B.P., Griffiths M., Khanom H., Taylor S.M., Neal J.W. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical and Experimental Immunology 2004, 138:430-438.
76. Moulton R.A., Mashruwala M.A., Smith A.K., Lindsey D.R., Wetsel R.A., Haviland D.L., Hunter R.L., Jagannath C. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice. Journal of Leukocyte Biology 2007, 82:956-967.
77. Nemali S., Siemsen D.W., Nelson L.K., Bunger P.L., Faulkner C.L., Rainard P., Gauss K.A., Jutila M.A., Quinn M.T. Molecular analysis of the bovine anaphylatoxin C5a receptor. Journal of Leukocyte Biology 2008, 84:537-549.
78. Nigrovic P.A., Malbec O., Lu B., Markiewski M.M., Kepley C., Gerard N., Gerard C., Daeron M., Lee D.M. C5a receptor enables participation of mast cells in immune complex arthritis independently of Fcγ receptor modulation. Arthritis and Rheumatism 2010, 62:3322-3333.
79. Nilsson U.R., Mandle R.J., McConnell-Mapes J.A. Human C3 and C5: Subunit structure and modifications by trypsin and C42-C423. Journal of Immunology 1975, 114:815-822.
80. Okinaga S., Slattery D., Humbles A., Zsengeller Z., Morteau O., Kinrade M.B., Brodbeck R.M., Krause J.E., Choe H.R., Gerard N.P., Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003, 42:9406-9415.
81. Peng Q., Li K., Wang N., Li Q., Asgari E., Lu B., Woodruff T.M., Sacks S.H., Zhou W. Dendritic cell function in allostimulation is modulated by C5aR signaling. Journal of Immunology 2009, 183:6058-6068.
82. Perianayagam M.C., Balakrishnan V.S., King A.J., Pereira B.J., Jaber B.L. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney International 2002, 61:456-463.
83. Perret J.J., Raspe E., Vassart G., Parmentier M. Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability. Biochemical Journal 1992, 288:911-917.
84. Proctor L.M., Woodruff T.M., Sharma P., Shiels I.A., Taylor S.M. Transdermal pharmacology of small molecule cyclic C5a antagonists. Advances in Experimental Medicine and Biology 2006, 586:329-345.
85. Pruitt S.K., Kirk A.D., Bollinger R.R., Marsh H.C., Collins B.H., Levin J.L., Mault J.R., Heinle J.S., Ibrahim S., Rudolph A.R., et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation 1994, 57:363-370.
86. Ricklin D., Lambris J.D. Complement-targeted therapeutics. Nature Biotechnology 2007, 25:1265-1275.
87. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: A key system for immune surveillance and homeostasis. Nature Immunology 2010, 11:785-797.
88. Riedemann N.C., Guo R.F., Neff T.A., Laudes I.J., Keller K.A., Sarma V.J., Markiewski M.M., Mastellos D., Strey C.W., Pierson C.L., Lambris J.D., Zetoune F.S., Ward P.A. Increased C5a receptor expression in sepsis. Journal of Clinical Investigation 2002, 110:101-108.
89. Riollet C., Rainard P., Poutrel B. Differential induction of complement fragment C5a and inflammatory cytokines during intramammary infections with Escherichia coli and Staphylococcus aureus. Clinical and Diagnostic Laboratory Immunology 2000, 7:161-167.
90. Robbins R.A., Russ W.D., Rasmussen J.K., Clayton M.M. Activation of the complement system in the adult respiratory distress syndrome. American Review of Respiratory Disease 1987, 135:651-658.
91. Rothermel E., Zwirner J., Vogt T., Rabini S., Gotze O. Molecular cloning and expression of the functional rat C5a receptor. Molecular Immunology 1997, 34:877-886.
92. Rus H., Cudrici C., Niculescu F. The role of the complement system in innate immunity. Immunological Research 2005, 33:103-112.
93. Rutkowski M.J., Sughrue M.E., Kane A.J., Ahn B.J., Fang S., Parsa A.T. The complement cascade as a mediator of tissue growth and regeneration. Inflammation Research 2010, 59:897-905.
94. Sanderson S.D., Cheruku S.R., Padmanilayam M.P., Vennerstrom J.L., Thiele G.M., Palmatier M.I., Bevins R.A. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. International Immunopharmacology 2003, 3:137-146.
95. Schieferdecker H.L., Schlaf G., Jungermann K., Gotze O. Functions of anaphylatoxin C5a in rat liver: Direct and indirect actions on nonparenchymal and parenchymal cells. International Immunopharmacology 2001, 1:469-481.
96. Schumacher W.A., Fantone J.C., Kunkel S.E., Webb R.C., Lucchesi B.R. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents and Actions 1991, 34:345-349.
97. Short A.J., Paczkowski N.J., Vogen S.M., Sanderson S.D., Taylor S.M. Response-selective C5a agonists: Differential effects on neutropenia and hypotension in the rat. British Journal of Pharmacology 1999, 128:511-514.
98. Shuster D.E., Kehrli M.E., Rainard P., Paape M. Complement fragment C5a and inflammatory cytokines in neutrophil recruitment during intramammary infection with Escherichia coli. Infection and Immunity 1997, 65:3286-3292.
99. Smith P.K., Shernan S.K., Chen J.C., Carrier M., Verrier E.D., Adams P.X., Todaro T.G., Muhlbaier L.H., Levy J.H. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials. Journal of Thoracic and Cardiovascular Surgery 2011, 142:89-98.
100. Stegall M.D., Diwan T., Raghavaiah S., Cornell L.D., Burns J., Dean P.G., Cosio F.G., Gandhi M.J., Kremers W., Gloor J.M. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. American Journal of Transplantation 2011, 11:2405-2413.
101. Stevens J.H., O'Hanley P., Shapiro J.M., Mihm F.G., Satoh P.S., Collins J.A., Raffin T.A. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. Journal of Clinical Investigation 1986, 77:1812-1816.
102. Stevens M.G., Van Poucke M., Peelman L.J., Rainard P., De Spiegeleer B., Rogiers C., Van de Walle G.R., Duchateau L., Burvenich C. Anaphylatoxin C5a-induced toll-like receptor 4 signaling in bovine neutrophils. Journal of Dairy Science 2011, 94:152-164.
103. Strachan A.J., Woodruff T.M., Haaima G., Fairlie D.P., Taylor S.M. A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. Journal of immunology 2000, 164:6560-6565.
104. Szebeni J., Baranyi L., Savay S., Bodo M., Milosevits J., Alving C.R., Bunger R. Complement activation-related cardiac anaphylaxis in pigs: Role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. American Journal of Physiology - Heart and Circulatory Physiology 2006, 290:H1050-H1058.
105. Taylor S.M., Sherman S.A., Kirnarsky L., Sanderson S.D. Development of response-selective agonists of human C5a anaphylatoxin: Conformational, biological, and therapeutic considerations. Current Medicinal Chemistry 2001, 8:675-684.
106. Tempero R.M., Hollingsworth M.A., Burdick M.D., Finch A.M., Taylor S.M., Vogen S.M., Morgan E.L., Sanderson S.D. Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin. Journal of Immunology 1997, 158:1377-1382.
107. Tizard I.R. Innate immunity: Inflammation. Veterinary Immunology 2000, 36-46. W.B. Saunders Company, Philadelphia. I. Tizard (Ed.).
108. Torres M., Forman H.J. Activation of several MAP kinases upon stimulation of rat alveolar macrophages: Role of the NADPH oxidase. Archives of Biochemistry and Biophysics 1999, 366:231-239.
109. Ulrich J.T., Cieplak W., Paczkowski N.J., Taylor S.M., Sanderson S.D. Induction of an antigen-specific CTL response by a conformationally biased agonist of human C5a anaphylatoxin as a molecular adjuvant. Journal of Immunology 2000, 164:5492-5498.
110. van der Pals J., Koul S., Andersson P., Gotberg M., Ubachs J.F., Kanski M., Arheden H., Olivecrona G.K., Larsson B., Erlinge D. Treatment with the C5a receptor antagonist ADC-1004 reduces myocardial infarction in a porcine ischemia-reperfusion model. BMC Cardiovascular Disorders 2010, 10:45.
111. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease 1998, Marcel Dekker Inc., New York.
112. Walport M.J. Complement. First of two parts. New England Journal of Medicine 2001, 344:1058-1066.
113. Ward P.A. The dark side of C5a in sepsis. Nature Reviews Immunology 2004, 4:133-142.
114. Ward P.A. Role of the complement in experimental sepsis. Journal of Leukocyte Biology 2008, 83:467-470.
115. Waters S.M., Brodbeck R.M., Steflik J., Yu J., Baltazar C., Peck A.E., Severance D., Zhang L.Y., Currie K., Chenard B.L., Hutchison A.J., Maynard G., Krause J.E. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction. Journal of Biological Chemistry 2005, 280:40617-40623.
116. Weissmann G. The pathogenesis of rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases 2006, 64:12-15.
117. Welch T.R. Complement in glomerulonephritis. Nature Genetics 2002, 31:333-334.
118. Welch T.R., Frenzke M., Witte D., Davis A.E. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clinical and Experimental Immunology 2002, 130:43-48.
119. Werfel T., Oppermann M., Schulze M., Krieger G., Weber M., Gotze O. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992, 79:152-160.
120. Wong A.K., Finch A.M., Pierens G.K., Craik D.J., Taylor S.M., Fairlie D.P. Small molecular probes for G-protein-coupled C5a receptors: Conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. Journal of Medicinal Chemistry 1998, 41:3417-3425.
121. Wong A.K., Taylor S.M., Fairlie D.P. Development of C5a receptor antagonists. Investigational Drugs 1999, 2:686-693.
122. Woodruff T.M., Strachan A.J., Sanderson S.D., Monk P.N., Wong A.K., Fairlie D.P., Taylor S.M. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001, 25:171-177.
123. Woodruff T.M., Strachan A.J., Dryburgh N., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis and Rheumatism 2002, 46:2476-2485.
124. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. Journal of Immunology 2003, 171:5514-5520.
125. Woodruff T.M., Arumugam T.V., Shiels I.A., Reid R.C., Fairlie D.P., Taylor S.M. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. Journal of Surgical Research 2004, 116:81-90.
126. Woodruff T.M., Pollitt S., Proctor L.M., Stocks S.Z., Manthey H.D., Williams H.M., Mahadevan I.B., Shiels I.A., Taylor S.M. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics 2005, 314:811-817.
127. Woodruff T.M., Crane J.W., Proctor L.M., Buller K.M., Shek A.B., de Vos K., Pollitt S., Williams H.M., Shiels I.A., Monk P.N., Taylor S.M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB Journal 2006, 20:1407-1417.
128. Woodruff T.M., Costantini K.J., Taylor S.M., Noakes P.G. Role of complement in motor neuron disease: Animal models and therapeutic potential of complement inhibitors. Advances in Experimental Medicine and Biology 2008, 632:143-158.
129. Woodruff T.M., Ager R.R., Tenner A.J., Noakes P.G., Taylor S.M. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Medicine 2009, 12:179-192.
130. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Molecular Immunology 2011, 48:1631-1642.
131. Xiao H., Jennette J.C., Dairaghi D.J., Ertl L., Baumgart T., Miao S., Powers J.P., Seitz L.C., Wang Y., Hu P., Falk R.J., Schall T.J., Jaen J.C. The human C5a receptor (hC5aR) antagonist CCX168 effectively ameliorates a model of ANCA glomerulonephritis (GN) in hC5aR knock-in mice. Arthritis and Rheumatism 2010, 62:2048.
132. Ye R.D. Regulation of nuclear factor kappaB activation by G-protein-coupled receptors. Journal of Leukocyte Biology 2001, 70:839-848.
133. Zhang H., Qin G., Liang G., Li J., Barrington R.A., Liu D.X. C5aR-mediated myocardial ischemia/reperfusion injury. Biochemical and Biophysical Research Communications 2007, 357:446-452.